Tag

Merck

7 stories

Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3

Merck's MK-2010 posted a 55% unconfirmed overall response rate among 11 previously untreated PD-L1-positive non-small cell lung cancer patients, the first…

Deals 5 days ago

Bain Built $300M Beeline Medicines on 5 BMS Autoimmune Programs

Bain Capital put $300 million into Beeline Medicines at launch, licensing five autoimmune programs from Bristol Myers Squibb to build its next specialty…

FDA 6 days ago

IDEAYA Targets FDA for Darovasertib After Phase 3 Doubles PFS to 6.9 Months

Darovasertib, IDEAYA Biosciences and Servier's PKC inhibitor for metastatic uveal melanoma, more than doubled median progression-free survival in its Phase…

Deals Apr 9, 2026

Paid $20M Upfront, Roche Extends C4T Molecular Glue Deal

Roche is paying $20 million upfront for access to two degrader-antibody conjugate (DAC) programs from C4 Therapeutics, with more than $1 billion in…

FDA Apr 8, 2026

Merck Reworks Zhifei China Vaccine Deal

Merck renegotiated its China vaccine supply agreement with distribution partner Zhifei.

Deals Apr 8, 2026

Merck Cut Terns Bid by $1B After Leukemia Data Missed

Merck cut its Terns offer from $7.7B to $6.7B after Phase 1 leukemia data disappointed. The rival bidder walked entirely.

Deals Apr 7, 2026

Eli Lilly Bets on Orexins — Same Playbook That Made Tirzepatide a Blockbuster

Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.